Prognostic value of preoperative von Willebrand factor plasma levels in patients with Glioblastoma. (28th May 2016)

• Record Type: Journal Article
• Authors: Marfia, Giovanni; Navone, Stefania Elena; Fanizzi, Claudia; Tabano, Silvia; Pesenti, Chiara; Abdel Hadi, Loubna; Franzini, Andrea; Caroli, Manuela; Miozzo, Monica; Riboni, Laura; Rampini, Paolo; Campanella, Rolando
• Is Part Of: Cancer medicine. Volume 5:Number 8(2016:Aug.)
• Page Start: 1783
• Page End: 1790
• Publication Date: 2016-05-28
• Subjects: Angiogenesis -- brain tumor -- Glioblastoma -- glioma. -- vascular endothelial growth factor -- von Willebrand Factor; 616.994005
• DOI: 10.1002/cam4.747
• Languages: English
• ISSNs: 2045-7634

Abstract

Abstract: Circulating biomarker for malignant gliomas could improve both differential diagnosis and clinical management of brain tumor patients. Among all gliomas, glioblastoma (GBM) is considered the most hypervascularized tumor with activation of multiple proangiogenic signaling pathways that enhance tumor growth. To investigate whether preoperative antigen plasma level of von Willebrand Factor (VWF:Ag) might be possible marker for GBM onset, progression, and prognosis, we retrospectively examined 57 patients with histological diagnosis for GBM and 23 meningiomas (MNGs), benign intracranial expansive lesions, enrolled as controls. Blood samples were collected from all the patients before tumor resection. Plasma von Willebrand Factor (VWF):Ag levels were determined by using a latex particle‐enhanced immunoturbidimetric assay. The median levels of vWF:Ag were significantly higher in GBMs than in meningiomas (MNGs) (183 vs. 133 IU/dL, P = 0.01). The cumulative 1‐year survival was significantly shorter in patients with VWF:Ag levels> 200 IU/dL than in those with levels <200 IU/dL and increased VWF levels were associated with a threefold higher risk of death in GBM patients. Our data suggest that VWF:Ag could be a circulating biomarker of disease malignancy, that could be considered, in association with other genetic and epigenetic factors, currently available in the GBM management. Future studies should investigate whether plasma VWF:Ag levels could also be used to monitor therapeutic effects and whether it may have a prognostic value. Abstract : Circulating biomarker for malignant glioblastoma could improve both differential diagnosis and clinical management of brain tumor patients. Plasma von Willebrand Factor (VWF):Ag levels were determined in 80 patients (57 glioblastoma and 23 meningiomas). The median levels of vWF:Ag were significantly higher in glioblastoma (GBMs) than in meningiomas (MNGs) and the cumulative 1‐year survival was significantly shorter in patients with VWF:Ag levels >200 IU/dL than in those with levels <200 IU/dL and increased VWF levels were associated with a threefold higher risk of death in GBM patients. Our data suggest that VWF:Ag could be a circulating biomarker of disease malignancy, that could be considered, in association with other genetic and epigenetic factors, currently available in the GBM management.